Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 345.36 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; titanium dioxide; macrogol 400; povidone - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 230.24 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 400; magnesium stearate; calcium hydrogen phosphate dihydrate - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 115.12 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate dihydrate; povidone; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.36 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; titanium dioxide; macrogol 400; povidone - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.24 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 400; magnesium stearate; calcium hydrogen phosphate dihydrate - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 115.12 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate dihydrate; povidone; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

United States - English - NLM (National Library of Medicine)

profounda, inc. - miltefosine (unii: 53ey29w7ec) (miltefosine - unii:53ey29w7ec) - miltefosine 50 mg - impavido (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: limitations of use: impavido is contraindicated in patients who are pregnant. based on animal data, miltefosine may cause fetal harm. [see boxed warning, warnings and precautions (5.1) and use in specific populations (8.1)]. impavido is contraindicated in patients who have sjögren-larsson-syndrome [see clinical pharmacology (12.3)] . impavido is contraindicated in patients who are hypersensitive to miltefosine or any impavido excipients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to impavido during pregnancy. healthcare providers are encouraged to register patients by calling 1-866-588-5405. risk summary impavido is contraindicated during pregnancy. based on data from animal reproduction studies, impavido may cause embryo-fetal toxicity when administered to pre

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - escitalopram oxalate, quantity: 25.552 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; macrogol 400; hypromellose; microcrystalline cellulose; purified talc; titanium dioxide; colloidal anhydrous silica - treatment of major depression, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder.